Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00876 vs ISRG, BDX, MDLN: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, Kaisa Health Group Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaisa Health Group Holdings Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kaisa Health Group Holdings's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Kaisa Health Group Holdings's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaisa Health Group Holdings (HKSE:00876) has a Buyback Yield % of 0.00 as of Aug. 23, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Kaisa Health Group Holdings and its competitors. According to the industry distribution chart, Kaisa Health Group Holdings ranks #999999 out of 334 companies in the Medical Devices & Instruments industry.
Is Kaisa Health Group Holdings' Buyback Yield % too high?
Kaisa Health Group Holdings' current Buyback Yield % is 0.00. Based on the distribution chart, Kaisa Health Group Holdings ranks #999999 out of 334 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kaisa Health Group Holdings has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kaisa Health Group Holdings' Buyback Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Kaisa Health Group Holdings ranks #999999 out of 334 companies for Buyback Yield %. This places Kaisa Health Group Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Kaisa Health Group Holdings and its competitors. Kaisa Health Group Holdings's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaisa Health Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kaisa Health Group Holdings (HKSE:00876) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.94, compared to a current price of HK$1.92 — trading 104.3% above its estimated fair value. The current Buyback Yield % is 0.00. Kaisa Health Group Holdings' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Kaisa Health Group Holdings (HKSE:00876), the current Buyback Yield % is 0.00 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaisa Health Group Holdings (HKSE:00876) Overvalued in 2026?
Based on GuruFocus' analysis, Kaisa Health Group Holdings stock appears to be overvalued.
The current stock price of HK$1.92 is trading 104.3% above its estimated GF Value™ of HK$0.94.
GuruFocus considers Kaisa Health Group Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00876:
Buyback Yield %: 0.00
GF Value™: HK$0.94 vs. price of HK$1.92 (104.3% above fair value)
No single metric tells the full story. See the HKSE:00876 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaisa Health Group Holdings Ltd, through its subsidiaries are mainly engaged in the manufacturing and sale of dental prosthetics and implant instruments, and the provision of sports rehabilitation services. The Group operates in two reportable segments: Dental Business, which consists of manufacturing and trading in dental products; and the Health Care Business, which provides services for sport rehabilitation, including postoperative rehabilitation, sports injury rehabilitation, chronic pain, scoliosis, deformity correction, other rehabilitation services, and health leisure business. The majority of its revenue is generated from the Dental business segment. Geographically, the Group generates maximum revenue from the People's Republic of China, and the rest from other countries.
37GF Score
Get the complete analysis for HKSE:00876
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00876 has been successfully added to your 
